Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E16.93 EPS (ttm)11.00 Insider Own0.20% Shs Outstand728.68M Perf Week0.22%
Market Cap135.67B Forward P/E14.53 EPS next Y12.81 Insider Trans-0.56% Shs Float728.62M Perf Month-0.15%
Income8.17B PEG3.87 EPS next Q3.10 Inst Own80.60% Short Float1.13% Perf Quarter3.91%
Sales23.05B P/S5.89 EPS this Y13.10% Inst Trans-0.01% Short Ratio3.32 Perf Half Y15.46%
Book/sh43.22 P/B4.31 EPS next Y1.86% ROA10.40% Target Price189.70 Perf Year14.49%
Cash/sh53.83 P/C3.46 EPS next 5Y4.38% ROE26.60% 52W Range133.64 - 191.10 Perf YTD27.34%
Dividend4.60 P/FCF18.62 EPS past 5Y20.50% ROI13.00% 52W High-2.57% Beta1.40
Dividend %2.47% Quick Ratio5.80 Sales past 5Y8.10% Gross Margin82.20% 52W Low39.32% ATR3.14
Employees19200 Current Ratio6.20 Sales Q/Q2.10% Oper. Margin44.70% RSI (14)58.61 Volatility1.70% 1.58%
OptionableYes Debt/Eq1.11 EPS Q/Q17.80% Profit Margin35.50% Rel Volume1.50 Prev Close181.90
ShortableYes LT Debt/Eq1.06 EarningsOct 25 AMC Payout38.80% Avg Volume2.48M Price186.19
Recom2.40 SMA200.26% SMA503.54% SMA2009.86% Volume3,731,575 Change2.36%
Sep-28-17Reiterated Mizuho Buy $183 → $198
Sep-15-17Initiated RBC Capital Mkts Sector Perform $192
Jul-11-17Resumed Jefferies Buy
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Oct-17-17 05:59PM  "Fast Money" final trades: MU, PYPL and more CNBC Videos
05:10PM  Technician says this one hot sector is about to heat up CNBC Videos
09:44AM  Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen Zacks
Oct-16-17 04:00PM  Amgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes PR Newswire
03:59PM  Pharma Industry Outlook - October 2017 Zacks
Oct-13-17 11:18AM  Can Biotech Stay Healthy Through the End of 2017?
Oct-12-17 09:00AM  Amgen Foundation Awards Khan Academy $3 Million To Support Development Of Free Comprehensive Biology Lessons PR Newswire
Oct-11-17 05:58PM  Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down Investor's Business Daily
01:14PM  Mylan Receives CRL for Neulasta Biosimilar
08:07AM  Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit Zacks
Oct-10-17 07:00PM  Amgen Wins Reprieve on Its 2nd-Best-Selling Drug Motley Fool
11:05AM  Amgen Puerto Rico Staff Keeping Plant Open Despite Personal Losses From Hurricane Maria Forbes
11:00AM  Amgen Label Expansion Application for Prolia Accepted by FDA Zacks
10:38AM  Tezepelumab Could Help Amgen Develop Its Inflammation Franchise Market Realist
09:10AM  Amgens Pipeline Could Boost Its Long-Term Growth Opportunities Market Realist
07:41AM  If Approved, Aimovig Could Strengthen Amgens Neurology Portfolio Market Realist
Oct-09-17 04:00PM  FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis PR Newswire
02:28PM  [$$] Ruling Goes Regeneron's Way
10:39AM  Biosimilars Could Boost Amgens Revenue Growth Market Realist
10:20AM  Forget Teva (TEVA), Buy These 5 Drug Stocks Instead Zacks
10:13AM  Cancer Space Last Week Update: Pipeline Expansion in Focus Zacks
09:13AM  Repatha Could Be Amgens Long-Term Growth Driver Market Realist
08:01AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
07:44AM  Analysts Recommendations for Amgen in October 2017 Market Realist
Oct-08-17 08:01AM  AbbVie's Fast Becoming a Top Stock to Buy Now Motley Fool
Oct-07-17 10:43AM  3 Blockbuster Drugs That Still Cost More Than They Should Motley Fool
Oct-06-17 07:00PM  3 Top Stocks Wall Street Insiders Love Motley Fool
06:27PM  FDA: Drug shortages possible due to Puerto Rico power outage Associated Press
05:37PM  Why Regeneron's Patent Win Is Worse For Amgen Than You Think Investor's Business Daily
04:01PM  Amgen And LabCentral Open Nomination Process For Lab Residency PR Newswire
09:00AM  Regeneron and Sanofi Get Favorable Ruling Against Amgen Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Amgen and Regeneron ACCESSWIRE
07:18AM  Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now? Motley Fool
Oct-05-17 04:50PM  Regeneron Pops After Judge Tosses Ban On Amgen-Rivaling Med Investor's Business Daily
04:30PM  First Randomized Study To Evaluate IMLYGIC® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology PR Newswire
01:51PM  [$$] Appeals Court Rules Against Amgen in Patent Case The Wall Street Journal
01:14PM  U.S. court reverses ban on sale of Regeneron, Sanofi cholesterol drug Reuters
01:01PM  Regeneron spiking on court ruling vs. Amgen CNBC Videos
11:13AM  Why Amgen is Sliding
10:32AM  AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why Zacks
03:00AM  Stocks With Rising Relative Strength: Amgen Investor's Business Daily
Oct-04-17 04:25PM  CytomX Breaks Out On Mash-Up With Amgen In Immuno-Oncology Investor's Business Daily
03:49PM  Amgen, CytomX Join in Immuno-Oncology Collaboration
02:00PM  Why Biotech's Rally May Push These 8 Stocks Even Higher Investopedia
09:11AM  Amgen Enters Into an Immuno-Oncology Partnership With CytomX Zacks
07:54AM  Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation Zacks
Oct-03-17 09:00PM  Why Shares in AbbVie Soared 18% in September Motley Fool
05:07PM  CytomX stock rockets 35% after deal with Amgen MarketWatch
04:15PM  Earnings Win Lifts This Sector; 2 Top Equity Plays In Buy Zone Investor's Business Daily
04:05PM  Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology PR Newswire
09:30AM  3 Top-Ranked Big Biotech Stocks to Buy Now Zacks
Oct-02-17 11:00PM  [$$] Stock market winners of 2008's crash had one thing in common Financial Times
04:02PM  AbbVie Patent Deal Staves Off Amgen Competition, But Others Lurk Investor's Business Daily
12:18PM  Plenty Of Opportunity In AbbVie, Even After Recent Run Benzinga
11:38AM  AbbVie Stock Upgraded: What You Need to Know Motley Fool
10:03AM  AbbVie: Better Late Than Never
Sep-29-17 03:09PM  AbbVie, Amgen Resolve Humira Patent Dispute
11:55AM  AbbVie's Humira Is an Ageless Wonder Bloomberg
10:44AM  AbbVie and Applied Materials Rose on September 28 Market Realist
09:28AM  How Will Trump's Proposed Tax Reform Impact Drug Companies? Zacks
09:25AM  Ligand's Captisol Deals Set to Drive Growth in the Long Run Zacks
07:24AM  Amgens rival to AbbVies Humira to launch in 2023 MarketWatch
06:04AM  How Good Is AbbVie's Humira Deal With Amgen? Motley Fool
12:07AM  AbbVie, Amgen Reach Settlement in Humira Patent Dispute The Wall Street Journal
Sep-28-17 05:44PM  AbbVie, Amgen Reach Humira Settlement The Wall Street Journal
04:52PM  Why Amgen's Drug Win Sent AbbVie Stock Into The Stratosphere Investor's Business Daily
04:30PM  Why BlackBerry, AbbVie, and bluebird bio Jumped Today Motley Fool
12:46PM  AbbVie: Has the Humira Cloud Lifted?
09:50AM  UPDATED: Under Amgen and AbbVie agreement, rival drug to AbbVie's Humira expected to launch in 2023 MarketWatch
08:00AM  Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA PR Newswire
Sep-27-17 03:00PM  5 Stocks That May Win Big FromTax Reform Investopedia
10:25AM  Short Sellers Hike Bets in Major Biotechs 24/7 Wall St.
08:01AM  Hurricane Maria devastation in Puerto Rico could cause drug shortages elsewhere MarketWatch
08:01AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
07:31AM  Trade of the Day: Amgen, Inc. (AMGN) Stock Has Plenty More Upside InvestorPlace
Sep-26-17 04:00PM  Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China PR Newswire
11:44AM  These Companies Gain If Trump's Foreign Profit Relief Plan Passes Investor's Business Daily
08:25AM  Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues Zacks
08:00AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
06:00AM  Why Risky Biotechs Are Rising as Tech Stocks Slump Investopedia
Sep-25-17 09:47AM  Amgen reaffirms 2017 guidance in wake of Hurricane Maria MarketWatch
09:00AM  Amgen Provides Update On Hurricane Maria PR Newswire
Sep-22-17 04:53PM  Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts PR Newswire
06:00AM  Gilead, Amgen, and Biogen May Lift Biotech Higher Investopedia
Sep-21-17 10:25AM  Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake Zacks
08:00AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
Sep-20-17 08:01PM  AMGEN (AMGN) ALERT: Johnson Fistel Announces Investigation of Amgen Inc.; Investors that Bought Before March 17, 2017, Encouraged to Contact the Firm PR Newswire
01:00PM  deCODE Study Reveals an Ancient Achilles Heel in the Human Genome PR Newswire
08:00AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
Sep-19-17 08:31PM  Amgen challenge to Genentech $6 billion cancer drug OK'd by FDA American City Business Journals
09:40AM  Is Amgen (AMGN) a Great Stock for Value Investors? Zacks
08:02AM  How This Immigrant Entrepreneur Built A $5 Billion Healthcare Company Forbes
Sep-18-17 01:06PM  We're not chasing electric utilities: Heartland Financial... CNBC Videos
11:35AM  Gilead Sciences: Is The Kite Deal Too Little, Too Late?
05:00AM  FDA Clears Biotech Drug Copycats, But Buying Them Isnt So Easy Bloomberg
Sep-17-17 12:17PM  3 Great Income Stocks That Could Double Their Dividends Motley Fool
Sep-15-17 10:05PM  FDA Approves First 'Biosimilar' for Cancer Treatment
05:46PM  Top Research Reports for Philip Morris, Amgen & Union Pacific Zacks
01:18PM  Why Amgen, Lilly, J&J Are Interested In These Small Biotechs Investor's Business Daily
10:33AM  Amgen/Allergan's Avastin Biosimilar Secures FDA Approval Zacks
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; Array BioPharma Inc.; Syngene International Limited; and CytomX Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harper Sean EEVP, Research & DevelopmentOct 09Sale185.951,525283,57459,156Oct 10 08:29 PM
BALTIMORE DAVIDDirectorMay 31Sale153.933,700569,54131,159Jun 02 07:21 PM
Patton Cynthia MSVP & CCOMay 24Sale154.402,922451,16421,292May 24 07:35 PM